On Feb. 16, 2018, JCO Clinical Cancer Informatics (JCO CCI) published its first special collection of articles. This collection highlights ways in which sharing cancer research data is now possible through individual networks, including ASCO’s CancerLinQ®.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
On February 12, the White House released its Fiscal Year (FY) 2019 budget proposal, which included several provisions and budget changes of interest to the cancer community. While the proposal is not binding, it does provide a view into some of the Administration’s goals and budget priorities for the year.
As deadlines draw near for submitting data for the 2017 Merit-based Incentives Payment System (MIPS) performance period, CMS has created a Top Ten List of things to know and do before the March deadline, along with important dates to remember.
On February 14, 2018, the Food and Drug Administration approved apalutamide (Erleada™, Janssen Biotech, Inc.) for patients with non-metastatic castration-resistant prostate cancer (NM-CRPC).
Biosimilars have rapidly proliferated in the cancer care landscape, leaving many providers unclear about the full impact these products will have on the care they deliver to patients. “American Society of Clinical Oncology Statement: Biosimilars in Oncology,” published in the Journal of Clinical Oncology, examines a range of issues to help ASCO members better understand the impact of biosimilars on oncology care.
Robin Zon, MD, FACP, FASCO, a medical oncologist at Michiana Hematology Oncology and last year’s ASCO Advocate of the Year, joined ASCO CEO Dr. Clifford Hudis this month to discuss Congressional advocacy and the role it plays in shaping cancer-related policies.
ASCO’s Quality Oncology Practice Initiative (QOPI®) Round 1 of reporting opened for registration on Feb. 5; data abstraction will open on Tuesday, Feb. 27 and close on Friday, June 1.
Congress passed the “Bipartisan Budget Act of 2018,” which funds the federal government through March 23, 2018, raises the federal budget caps for the next two years, and addresses several policies of importance to the cancer community.
The American Society of Clinical Oncology (ASCO) commends Congress for passing a continuing resolution that includes an important correction to the Merit-based Incentive Payment System. We are also pleased to see a budget deal that commits to at least a $2 billion funding increase for the National Institutes of Health (NIH) to reclaim America’s leadership in cancer research and continue building on our tremendous progress towards understanding, preventing, and treating cancer.
On February 7, 2018, the Food and Drug Administration (FDA) approved abiraterone acetate (Zytiga®, Janssen Biotech Inc.) tablets in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer (CSPC).
ASCO applauds a provision in the continuing resolution (CR) passed by the House of Representatives yesterday that will ensure that payment adjustments under the Merit-based Incentive Payment System (MIPS) are not applied to Medicare Part B drug reimbursement. ASCO has strongly advocated for this change since the release of a proposed Quality Payment Program rule by the Centers for Medicare and Medicaid Services in June of 2017
ASCO today released its review of leading oncology pathway vendors in the United States. "Oncology Clinical Pathways: Charting the Landscape of Pathway Providers," published in the Journal of Oncology Practice (JOP), examines the clinical pathways offered by six commercial vendors using the society's criteria for high-quality clinical pathways.
ASCO is one of nearly 40 organizations—collectively representing millions of patients with serious and life-threatening diseases—urging Members of Congress to oppose two “right-to-try” (RTT) bills currently under consideration. In a letter to House leadership, the organizations expressed their support for patient access to promising unapproved therapies, but stated that the legislation under consideration would fail to actually expand such access, and more importantly, could do more harm than good to seriously ill patients.
The ASCO in Action Podcast provides analysis and commentary on cancer policy and practice issues. The show features robust discussion on the most pressing policy and practice issues impacting the cancer care delivery system and individuals with cancer.
ASCO provided comments to the Federation of State Medical Boards (FSMB) on a proposed position statement entitled “Compounding of Medications by Physicians.” The society appreciates FSMB’s efforts to ensure the safety of compounded medications, but believes that if finalized in its current form, the FSMB’s position statement would lead to confusion among cancer care providers and create barriers to providing chemotherapy to patients with cancer. ASCO urges FSMB to make clarifications and specific edits to the proposal, or to delay final approval of the position statement to allow time for refinements.